Xcellerated T CellsTM in Patients With Multiple Myeloma
Completed · Phase 2
Conditions studied: Multiple Myeloma
In brief
This trial is a phase II, randomized study of patients with multiple myeloma. All patients will receive Xcellerated T Cells, with or without prior fludarabine therapy. 15 patients in each study arm will be followed for 6 months.
Key facts
- Study ID
- NCT00078065
- Run by
- Xcyte Therapies
- People needed
- 30
- Starts
- 2003-11-01
- Expected to finish
- 2004-06-01
- Last updated by the study team
- 2005-11-11
Who can join
Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Oncotherapeutics — Los Angeles, California, United States
- University of California, San Diego — San Diego, California, United States
- University of California, San Francisco — San Francisco, California, United States
- Johns Hopkins Medical Institute — Baltimore, Maryland, United States
- Center for Cancer & Blood Disorders — Bethesda, Maryland, United States
- Washington University School of Medicine — St Louis, Missouri, United States
- Hackensack University Medical Center — Hackensack, New Jersey, United States
- Oregon Health Sciences University — Portland, Oregon, United States
- Cancer Centers of the Carolinas — Greenville, South Carolina, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.